These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29363548)

  • 1. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
    Sharma SK; Chow A; Monette S; Vivier D; Pourat J; Edwards KJ; Dilling TR; Abdel-Atti D; Zeglis BM; Poirier JT; Lewis JS
    Cancer Res; 2018 Apr; 78(7):1820-1832. PubMed ID: 29363548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.
    Oldham RJ; Mockridge CI; James S; Duriez PJ; Chan HTC; Cox KL; Pitic VA; Glennie MJ; Cragg MS
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.
    Li F; Ulrich ML; Shih VF; Cochran JH; Hunter JH; Westendorf L; Neale J; Benjamin DR
    Mol Cancer Ther; 2019 Apr; 18(4):780-787. PubMed ID: 30824607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies.
    Maron R; Schechter B; Nataraj NB; Ghosh S; Romaniello D; Marrocco I; Noronha A; Carvalho S; Yarden Y; Sela M
    Biochem Biophys Res Commun; 2019 May; 513(1):219-225. PubMed ID: 30952434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.
    Kudo K; Imai C; Lorenzini P; Kamiya T; Kono K; Davidoff AM; Chng WJ; Campana D
    Cancer Res; 2014 Jan; 74(1):93-103. PubMed ID: 24197131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
    van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
    J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis.
    Cao Q; Cai W; Niu G; He L; Chen X
    Clin Cancer Res; 2008 Oct; 14(19):6137-45. PubMed ID: 18829492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.
    Tan PS; Gavin AL; Barnes N; Sears DW; Vremec D; Shortman K; Amigorena S; Mottram PL; Hogarth PM
    J Immunol; 2003 Mar; 170(5):2549-56. PubMed ID: 12594281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
    Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
    J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.